Skip to main content
Premium Trial:

Request an Annual Quote

Roche, ChanTest Ink Deal to Evaluate Safety of Compounds

NEW YORK (GenomeWeb News) – Roched has entered into an agreement with ChanTest to evaluate the safety of potential drug compounds.

Under the terms of the deal announced today, ChanTest, an ion channel screening provider, will use Roche's xCelligence System RTCA Cardio Instrument and Cellular Dynamics International's iCell Cardiomyocytes to evaluate pharmacological responses to a number of compounds that have been selected based on their known effects on ion channels.

CDI's iCell Cardiomyocytes are human-induced pluripotent stem cell-derived cadiomyocytes.

Financial terms of the deal were not disclosed.

ChanTest's work will include assessment of acute and long-term exposure conditions. Results from the evaluation will be compared to results from conventional methods and to known data from preclinical and clinical studies.